New insights on liver injury in men taking body building supplements
- Date:
- April 3, 2019
- Source:
- Wiley
- Summary:
- Forty-four men with liver injury, attributed to over-the-counter bodybuilding supplements, experienced a uniform and distinctive pattern of signs and symptoms that were often prolonged, difficult to treat, and accompanied by disability and weight loss, according to a new study.
- Share:
In a study reported in Alimentary Pharmacology & Therapeutics, 44 men with liver injury, attributed to over-the-counter bodybuilding supplements, experienced a uniform and distinctive pattern of signs and symptoms that were often prolonged, difficult to treat, and accompanied by disability and weight loss.
All participants in the study, who were enrolled in the National Institute of Health-supported Drug-Induced Liver Injury Network, had jaundice (a yellowing of the eyes and skin) and most had generalized itching leading to hospitalization in 71 percent of patients, although none died or needed a liver transplant.
Investigators commonly found that the ingested products often contained illicit anabolic steroids not accurately listed on the label.
"Anabolic steroids should only be used under the strict supervision of a physician," said lead author Dr. Andrew Stolz, of the University of Southern California, Los Angeles. "Patients need to inform their care providers if they are taking any form of nutritional supplement and should be especially leery of bodybuilding supplements, which may contain illicit or USA Drug Enforcement Administration controlled anabolic steroids."
Journal Reference:
- Andrew Stolz, Victor Navarro, Paul H. Hayashi, Robert J. Fontana, Huiman X. Barnhart, Jiezhun Gu, Naga P. Chalasani, Maricruz M. Vega, Herbert L. Bonkovsky, Leonard B. Seeff, Jose Serrano, Bharathi Avula, Ikhlas A. Khan, Elizabeth T. Cirulli, David E. Kleiner, Jay H. Hoofnagle. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology & Therapeutics, 2019; DOI: 10.1111/apt.15211
Cite This Page: